794 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again http://www.zacks.com/stock/news/705042/why-amgen-amgn-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-705042 Jan 06, 2020 - Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition https://www.fool.com/investing/2019/12/21/how-gilead-sciences-is-helping-fund-bristol-myers.aspx?source=iedfolrf0000001 Dec 21, 2019 - But the big biotech isn't a happy camper about its contribution.
AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU http://www.zacks.com/stock/news/678331/abbvies-jak-inhibitor-rinvoq-receives-approval-for-ra-in-eu?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-678331 Dec 19, 2019 - AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives approval in Europe for treating rheumatoid arthritis under the trade name of Rinvoq.
Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More http://www.zacks.com/stock/news/677081/biotech-stock-roundup-amrn-stock-up-pipeline-updates-from-gild-biib-amgn-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-677081 Dec 18, 2019 - The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.
The Zacks Analyst Blog Highlights: Apple, Cisco Systems, Oracle, HSBC and Amgen http://www.zacks.com/stock/news/676830/the-zacks-analyst-blog-highlights-apple-cisco-systems-oracle-hsbc-and-amgen?cid=CS-ZC-FT-press_releases-676830 Dec 18, 2019 - The Zacks Analyst Blog Highlights: Apple, Cisco Systems, Oracle, HSBC and Amgen
Top Analyst Reports for Apple, Cisco & Oracle http://www.zacks.com/research-daily/674935/top-analyst-reports-for-apple-cisco-oracle?cid=CS-ZC-FT-research_daily-674935 Dec 17, 2019 - Top Analyst Reports for Apple, Cisco & Oracle
3 Reasons This Biotech is a Buy for Risk-Averse Investors https://www.fool.com/investing/2019/12/13/reasons-biotech-a-buy-for-risk-averse-amgen.aspx?source=iedfolrf0000001 Dec 13, 2019 - Biotech can be a risky sector for those interested in healthcare stocks, but Amgen has found a way to manage the risk and reap the rewards.
Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar http://www.zacks.com/stock/news/665488/biotech-stock-roundup-ash-data-in-focus-amgen-gets-fda-nod-to-remicade-biosimilar?cid=CS-ZC-FT-analyst_blog|stock_roundup-665488 Dec 11, 2019 - The biotech sector witnesses pipeline updates from the annual ASH meet.
Biotech ETFs Hit New Highs on Deal Activities http://www.zacks.com/stock/news/663878/biotech-etfs-hit-new-highs-on-deal-activities?cid=CS-ZC-FT-etf_news_and_commentary-663878 Dec 10, 2019 - Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
Healthpeak Amends & Extends Lease With Amgen in San Francisco http://www.zacks.com/stock/news/663733/healthpeak-amends-extends-lease-with-amgen-in-san-francisco?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-663733 Dec 10, 2019 - Healthpeak's (PEAK) lease amendment and extension with Amgen at the Britannia Oyster Point of the former offers flexibility in addressing lease-expiration issue at this property.

Pages: 1234567...80

<Page 2>